Abstract
This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e. polymorphonuclear cells or neutrophils, but can also activate monocytes and macrophages. The present knowledge, but also future direction for IgA- based drugs are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 35-9 |
| Number of pages | 5 |
| Journal | Molecular Immunology |
| Volume | 68 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Nov 2015 |
Keywords
- Animals
- Antigens, CD20
- Antineoplastic Agents
- B-Lymphocytes
- Gene Expression
- Humans
- Immunization, Passive
- Immunoglobulin A
- Immunoglobulin G
- Lymphocyte Depletion
- Macrophages
- Mice
- Monocytes
- Neoplasms
- Neutrophils
- Rituximab
- Antibody therapy
- IgA
- Immunotherapy